Health Journal Online

Tag: Percent

  • GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    The list of conditions that GLP-1 receptor agonists appear to protect against keeps getting longer. These drugs — which include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newly approved orforglipron (Foundayo) — were originally developed for type 2 diabetes before emerging as transformative obesity medications. Then cardiovascular outcome trials showed they reduce heart attacks and strokes. Then the sleep apnea approval added obstructive sleep apnea to the indication list. Then studies suggested reductions in kidney disease progression, non-alcoholic fatty liver disease, and alcohol dependence.

    And now, a major study presented at the American Society of Clinical Oncology Annual Meeting in Chicago in early June 2026 and reported widely on June 10, 2026 has added breast cancer to the rapidly expanding list of conditions that GLP-1 drugs appear to protect against — with an effect magnitude that has stunned the oncology community.

    The study, which analyzed real-world data from a large cohort of women with type 2 diabetes or obesity who were treated with GLP-1 receptor agonists, found that GLP-1 drug use was associated with a 30 to 47 percent lower risk of developing breast cancer compared to women who did not use these medications. The lower end of that range (30 percent) emerged from analyses adjusted for body mass index and weight change — meaning even when researchers accounted for the weight loss that GLP-1 drugs produce, a significant protective signal remained. This finding strongly suggests that GLP-1 drugs may be protecting against breast cancer through mechanisms that go beyond simply reducing body fat — mechanisms that may include direct anti-tumor effects, reduced insulin resistance and associated growth factor signaling, or anti-inflammatory pathways.

    Why This Finding Is Biologically Plausible

    The biological connection between metabolic dysfunction, obesity, insulin resistance, and breast cancer risk is well established. Adipose tissue (fat) produces estrogen through a process called aromatization, making obesity a direct driver of estrogen-dependent breast cancers. Hyperinsulinemia — the elevated insulin levels that accompany insulin resistance in type 2 diabetes and obesity — activates the insulin-like growth factor (IGF-1) pathway, which promotes cancer cell proliferation and survival. Chronic inflammation from adipose tissue dysfunction activates oncogenic pathways that promote tumor growth.

    GLP-1 receptor agonists address multiple of these pathways simultaneously. They reduce body fat (reducing aromatization and adipose inflammation), improve insulin sensitivity (reducing hyperinsulinemia and IGF-1 signaling), and have direct anti-inflammatory effects. Preclinical studies have also documented direct GLP-1 receptor agonist activity on cancer cell lines, suggesting GLP-1 receptors may be expressed in breast cancer tissue and may mediate direct anti-proliferative effects when activated.

    The study’s finding that the protective signal persists even after adjustment for weight and BMI is the most provocative result, because it suggests the drug’s biological effects — beyond simple caloric restriction and fat mass reduction — are contributing to cancer protection.

    What This Means for the 15 Million Americans on GLP-1 Drugs

    Approximately 15 million Americans are currently prescribed GLP-1 receptor agonists. The vast majority are taking them for type 2 diabetes or weight management. If the breast cancer protective signal seen in this study is confirmed in larger prospective trials and in controlled analyses, it would represent an additional major health benefit of these medications — one that could influence prescribing decisions, insurance coverage arguments, and cancer prevention discussions.

    The researchers caution that this is observational data from a real-world cohort, not a randomized controlled trial. Confounding variables — the possibility that GLP-1 drug users differ from non-users in ways that independently affect breast cancer risk — must be accounted for before these findings can be considered definitive. Prospective studies and potential randomized trials with cancer outcomes as endpoints are now being planned. The Phase 3 ORCA trial of semaglutide in high-risk cancer prevention populations is one ongoing effort that will provide higher-quality evidence.

    For women currently taking GLP-1 drugs for any indication, this study is not a recommendation to take them as cancer prevention without diabetes or obesity indication — rather, it is an important signal that the health benefits of these medications may be broader than previously understood.

    Frequently Asked Questions

    Q: What did the new GLP-1 and breast cancer study find?

    A: A real-world cohort study presented at ASCO 2026 found that women with type 2 diabetes or obesity who used GLP-1 receptor agonists had a 30–47% lower breast cancer risk compared to non-users. The effect persisted after adjustment for weight loss.

    Q: Does this mean women should take GLP-1 drugs specifically to prevent breast cancer?

    A: No. This is observational data, not a randomized trial. The finding is a promising signal that warrants further research, not a clinical recommendation for GLP-1 drugs as cancer prevention outside of established indications.

    Q: Why might GLP-1 drugs protect against breast cancer beyond weight loss?

    A: By reducing hyperinsulinemia, improving insulin sensitivity (lowering IGF-1 signaling), reducing adipose-tissue inflammation, and potentially through direct GLP-1 receptor activity on breast tissue — all mechanisms independent of weight loss.

    Q: Which GLP-1 drugs were included in the study?

    A: The study analyzed GLP-1 receptor agonist use broadly, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) among the most commonly used agents. Results were not limited to a specific drug within the class.

    Q: How does this new finding fit with the other cancer data on GLP-1 drugs?

    A: A 2024 Nature Medicine study documented lower incidence of multiple obesity-associated cancers in GLP-1 users. The 2026 ASCO breast cancer study adds specifically to that growing body of evidence suggesting GLP-1 drugs may have broad anti-cancer properties.

    Source link

  • CRISPR Gene Editing Achieves a Functional Cure for Sickle Cell Disease in 96 Percent of Patients — RUBY Trial Results in the New England Journal of Medicine Are Historic

    CRISPR Gene Editing Achieves a Functional Cure for Sickle Cell Disease in 96 Percent of Patients — RUBY Trial Results in the New England Journal of Medicine Are Historic

    The phrase “functional cure” is used carefully in medicine — it describes an outcome in which a disease’s effects are so effectively suppressed that the patient lives as though they do not have it, even if the underlying genetic cause remains. For sickle cell disease, a condition that has caused lifelong suffering, organ damage, and premature death for 100,000 Americans and millions globally, achieving a functional cure through gene editing is one of the most profound accomplishments medicine has produced in years.

    The RUBY Trial, published in the New England Journal of Medicine on April 1, 2026, has delivered exactly that result. Of 28 patients with severe sickle cell disease who were treated with renizgamglogene autogedtemcel (reni-cel) — a CRISPR-Cas12a gene editing therapy that modifies patients’ own blood-forming stem cells — 27 (96 percent) had no painful sickle cell crises for up to two years following treatment. Their average hemoglobin levels rose to near-normal levels, effectively restoring the oxygen-carrying capacity that sickle-shaped red blood cells cannot provide.

    “We have seen that a benefit of this CRISPR/Cas12a gene-editing technology is that there is no rejection, so it’s different from traditional bone marrow transplants, which is standard treatment for sickle cell patients currently,” said Dr. Rabi Hanna, lead author and chair of the Pediatric Hematology-Oncology and Blood and Bone Marrow Transplant Division at Cleveland Clinic Children’s, who led the multicenter trial sponsored by Editas Medicine. “Our aim has been to achieve a functional cure to help prevent any future damage caused by sickle cell disease, and these latest results are compelling.”

    How Reni-Cel Works — and Why Cas12a Matters

    Reni-cel uses CRISPR-Cas12a gene editing to target the promoter regions of the HBG1 and HBG2 genes — the switches that normally suppress fetal hemoglobin production after birth. By editing these promoters, reni-cel reactivates the production of fetal hemoglobin (HbF) in adult red blood cells. Since fetal hemoglobin does not sickle, its presence in sufficient quantities effectively dilutes or displaces the dysfunctional sickle hemoglobin, preventing the cell deformation that causes sickle cell crises, organ damage, and shortened life expectancy.

    This approach is distinct from Casgevy (exa-cel) — the first approved CRISPR therapy for sickle cell disease, using CRISPR-Cas9 to target BCL11A, a different suppressor of fetal hemoglobin. Reni-cel uses CRISPR-Cas12a, which has a different molecular structure and cutting mechanism from Cas9, and targets HBG1/HBG2 directly rather than through BCL11A. The two approaches achieve similar biological endpoints — fetal hemoglobin reactivation — through different molecular pathways, meaning they may offer complementary options for patients in whom one approach is less effective.

    The 28 patients — four of whom were treated at Cleveland Clinic Children’s — underwent a procedure in which their stem cells were first collected and taken to a laboratory where the gene editing was performed. They then received chemotherapy to clear their bone marrow, making room for the repaired cells, which were infused back into their bodies. Within weeks of engraftment, fetal hemoglobin levels began rising. Most patients’ hemoglobin reached near-normal values within the first several months — and the patients themselves experienced what the data describe: two years without a painful crisis.

    Access and What Comes Next

    Reni-cel is not yet FDA-approved. The RUBY Trial data represent Phase 1/2 trial results — sufficient to demonstrate safety and early efficacy, but additional confirmatory data and FDA submission will be needed before approval. Editas Medicine, the trial sponsor, is expected to proceed with regulatory submission based on these results. The cost challenge that affects Casgevy — approximately $2.2 million per patient — will also apply to reni-cel, making equitable access a critical policy question for the approximately 100,000 Americans with sickle cell disease, most of whom are Black or Latino, a demographic that has faced persistent underinvestment in sickle cell research and treatment infrastructure for decades.

    Frequently Asked Questions

    Q: What were the RUBY Trial results?

    A: 27 of 28 patients (96%) with severe sickle cell disease had zero painful sickle cell crises for up to two years after treatment with reni-cel. Their average hemoglobin levels rose to near-normal.

    Q: How is reni-cel different from Casgevy?

    A: Reni-cel uses CRISPR-Cas12a to edit the HBG1 and HBG2 fetal hemoglobin promoters directly. Casgevy uses CRISPR-Cas9 to target BCL11A. Both reactivate fetal hemoglobin but through different molecular pathways.

    Q: Is reni-cel FDA-approved?

    A: No. The RUBY Trial is Phase 1/2. FDA submission is expected based on these results. Casgevy is already FDA-approved and represents the current available option.

    Q: How many Americans have sickle cell disease?

    A: Approximately 100,000 Americans, disproportionately African American and Latino.

    Q: Why is gene editing potentially better than bone marrow transplant for sickle cell?

    A: Because patients use their own edited cells, eliminating the need for a matched donor and removing the risk of graft-versus-host disease — the immune attack that is the major complication of donor-based bone marrow transplants.

    Source link